Dabur gets NSE no objection for Sesa Care amalgamation scheme

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

DABUR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹510.50

prior close

₹508.10

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.7%+0.6% vs market

Personal Care peers, median of 12sector-2.4%+1.3% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Midcap 150 and 1.3 pts more than its Personal Care peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.2

15m

-0.0

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1-1.7+0.6-2.4+1.3

Next day

-1.1-1.3+0.2-0.6-0.5

-2.1-2.3+0.2-1.0-1.1

-1.5-1.4-0.1-0.4-1.1

-3.2-0.3-2.9-0.2-2.9

-2.6-0.3-2.3-1.2-1.4

-3.5-1.6-1.9-2.5-1.1

15d

-3.0-0.7-2.4+0.3-3.3

+1.6-0.1+1.7-0.7+2.4

+0.3+0.3+0.0+5.0-4.7

-8.5-6.6-2.0-4.4-4.2

UpDownMarket · Nifty Midcap 150Sector · Personal Care peers, median of 12Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dabur India has received NSE's no objection letter for the proposed amalgamation of Sesa Care Private Limited into Dabur India under Sections 230-232 of the Companies Act 2013. The scheme was first filed on May 26, 2025 and has now cleared NSE review, with conditions on disclosures to shareholders. Next step is filing the scheme with NCLT within 6 months. The deal still needs shareholder and creditor approvals.

Likely market impact

Positive - merger moves closer to completion, consolidating Sesa Care into Dabur. Awaiting NCLT and shareholder approvals.